
Athenagen Inc. began a phase I clinical trial of mecamylamine (ATG003), its eye drop therapy for age-related macular degeneration (AMD). Animal models showed efficacy of ATG003 as an alternative to current AMD therapies, which require needle injections directly in the eye. The randomized, placebo-controlled, ascending dose clinical trial is designed to evaluate ocular tolerability and safety for up to 14 days.